PH
Piper Heartland Healthcare Capital
Minneapolis, Minnesota, United StatesFounded 2022
Piper Heartland Healthcare Capital focuses on investing in innovative healthcare companies across the biotech, med-tech, and healthcare information sectors that demonstrate near-term public market prospects. Their strategy leverages Piper Sandler's extensive healthcare platform, including its banking, capital markets, and equity research expertise, to identify proprietary investment opportunities and support companies at crucial stages of their growth.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (75% of deals). Average disclosed round size is $175.2M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$221.4M
Top Stage
Series C
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Arbor Biotechnologies Inc | Series C | $73.9M | Mar 2025 |
 Alumis Inc | Series C | $259M | Mar 2024 |
| Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
 Artios Pharma Limited | Series C | $153M | Jul 2021 |
Top Co-Investors
Ally Bridge Group3 shared
Deep Track Capital3 shared
Temasek Holdings2 shared
ArrowMark Partners2 shared
Surveyor Capital2 shared
T. Rowe Price2 shared
ARCH Venture Partners2 shared
Omega Funds2 shared
Illumina Ventures1 shared
Janus Henderson Investors1 shared
Logos Capital1 shared
Ono Venture Investment1 shared
Ridgeback Capital1 shared
Section 321 shared
Tao Capital Partners1 shared
Tekla Capital Management1 shared
Woodline Partners1 shared
Vertex Pharmaceuticals1 shared
Qatar Investment Authority1 shared
Revelation Partners1 shared
Last updated: 12 April 2026